Conference Coverage

VIDEO: PPACMAN aims to advance the combined rheum-derm clinic approach in the community


 

REPORTING FROM AAD 18

There are now about 12 centers in North America with formal rheumatology-dermatology clinics for patients with psoriasis and psoriatic arthritis, including the one at Brigham and Women’s, where Dr. Merola and his colleagues have seen the “myriad benefits that come with having a combined clinic,” he said in a video interview at the annual meeting of the American Academy of Dermatology. The idea behind starting PPACMAN was to help form new clinics at academic centers but, also, “to start to catalyze local-regional partnerships in the community so we could get dermatologists and rheumatologists in the community to start interacting, communicating, [and] sharing patients,” he explained.


“The group is really very much focused on this mission of getting combined ... treatment models out there,” added Dr. Merola, president and chair of the board of PPACMAN, which is a 501c3 nonprofit organization.

In the interview, he discusses other benefits of the combined clinic model and other elements of the PPACMAN mission, including education and the potential for shared EMR templates.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Pages

Recommended Reading

Ixekizumab beats ustekinumab for fingernail psoriasis, hands down
MDedge Rheumatology
Meta-analysis: Lifestyle changes improve psoriasis
MDedge Rheumatology
Make a PEST of your psoriasis patients
MDedge Rheumatology
CV risk factors go undiagnosed, untreated in many psoriatic patients
MDedge Rheumatology
Get ready for certolizumab for psoriasis
MDedge Rheumatology
Here comes bimekizumab, the newest IL-17 inhibitor
MDedge Rheumatology
Risankizumab outpaced ustekinumab for complete clearance of plaque psoriasis
MDedge Rheumatology
Biologics have best chance of achieving PASI 90 in psoriasis
MDedge Rheumatology
Ustekinumab quells aortic inflammation in patients with severe psoriasis
MDedge Rheumatology
Could guselkumab be a disease-modifying agent in plaque psoriasis?
MDedge Rheumatology